Biotech is very much driven by stock-specific catalysts like clinical trial results and FDA drug approvals, so a good showing for the last three months of the year will also hinge on the outcome of some key events.

Here is a list of the biotech events with the most potential impact for the remainder of 2010:
  • The FDA advisory panel for Arena Pharmaceuticals' (ARNA) obesity drug lorcaserin on Sept. 16.
  • Amgen's results from a phase III study of denosumab in the prevention of prostate cancer.
  • Genzyme's ongoing M&A dance with Sanofi.
  • Presentation of hepatitis C drug data from Vertex Pharmaceuticals and Merck (MRK) at the American Association for the Study of Liver Disease annual meeting in November.
  • FDA's approval decision for Human Genome Sciences' (HGSI) lupus drug Benlysta on Dec. 9.
  • Likewise, the FDA's expected approval decision on Oct. 22 for the diabetes drug Bydureon from Amylin Pharmaceuticals (AMLN), Eli Lilly (LLY) and Alkermes (ALKS).
  • Medicare's national coverage determination meeting for Dendreon's prostate cancer vaccine Provenge on Nov. 17.
I previously put together a list of 21 drugs facing FDA approval decisions through the end of the year, so please check it out.

Here, too, is a list of important clinical trial results pending in 2010 and a calendar of biotech events for September.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes